AVITA Medical (NasdaqCM:RCEL) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsBen Atkins - VP of Investor RelationsCary Vance - Interim CEODavid O'Toole - CFOConference Call ParticipantsIan Arndt - Equity Research AnalystJosh Jennings - Equity Research AnalystRyan Zimmerman - Equity Research AnalystOperatorday, and thank you for standing by. Welcome to the AVITA Medical, Inc. fourth quarter and full-year 2025 earnings conference call. At this time, all participants are in listen-only ...

AVITA Medical (NasdaqCM:RCEL) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsBen Atkins - VP of Investor RelationsCary Vance - Interim CEODavid O'Toole - CFOConference Call ParticipantsIan Arndt - Equity Research AnalystJosh Jennings - Equity Research AnalystRyan Zimmerman - Equity Research AnalystOperatorday, and thank you for standing by. Welcome to the AVITA Medical, Inc. fourth quarter and full year 2025 earnings conference call. At this time, all participants are in listen-only ...

AVITA Medical (NasdaqCM:RCEL) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Speaker5day, and thank you for standing by. Welcome to the AVITA Medical, Inc. fourth quarter and full year 2025 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question during the session, you'll need to press star one one on your telephone. You will then hear an automated message advising your hand is raise ...

VALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights and Recent Business Updates Total revenue of $17.6 million, compared to $18.4 million in the fourth quarter of 2024, reflecting the lingering impact of reimb ...

Core Insights - AVITA Medical presented data from 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, showcasing the integrated use of its technologies RECELL, PermeaDerm, and Cohealyx in wound care [1][2][3] Group 1: Integrated Use of Technologies - The first surgeon-reported experience integrating RECELL, PermeaDerm, and Cohealyx was highlighted, demonstrating reduced need for painful dressing changes and avoiding long-distance follow-ups [3] - This integrated approach is particularly beneficial for rural and community hospitals with limited access to specialized burn services [3] Group 2: Clinical Findings - Initial findings from multicenter clinical trials on PermeaDerm and Cohealyx were presented, with full results expected in 2026 [4] - PermeaDerm showed early blood vessel growth and organized tissue formation without increased inflammation compared to traditional human skin for temporary coverage [5] - Cohealyx demonstrated cellular infiltration and early blood vessel formation within two weeks, preparing the wound for skin grafting without complications [6] Group 3: RECELL Evidence and Benefits - A systematic review of 27 peer-reviewed studies reinforced the benefits of RECELL, showing consistent trends in healing, reduced complications, and shorter hospital stays [7][10] - In older burn patients, adding RECELL to standard skin grafting resulted in nearly 16 days shorter hospital stays and fewer graft failures [9] - Patients treated with RECELL for deep partial-thickness burns spent about one-third less time in the hospital compared to traditional grafting methods [9] Group 4: Practical Applications - Surgeons are demonstrating how the staged use of AVITA Medical's advanced wound care technologies can improve healing and help hospitals manage limited resources [11]

Summary of AVITA Medical FY Conference Call Company Overview - **Company**: AVITA Medical (NasdaqCM:RCEL) - **Industry**: Medical Technology, specifically focused on burn treatment and wound care Key Points and Arguments 1. **Mission and Focus**: AVITA Medical is dedicated to patient care, emphasizing clinical data, innovation, and economic benefits for customers [2][4] 2. **Market Opportunity**: There are approximately 40,000 hospitalized burn patients annually, with many not receiving optimal care. AVITA's Resell product line aims to address this gap [4] 3. **Product Line**: The company offers several products including RECELL, RECELL GO, RECELL Micro, CoHelix, and PermeaDerm, which are designed for wound closure and healing [5][6] 4. **Economic Benefits**: The use of AVITA's products can lead to significant cost savings for hospitals, including a potential reduction of up to $42,000 in costs due to a 36% reduction in length of stay [14][20] 5. **Growth Strategy**: The company aims to penetrate existing accounts more deeply, currently only achieving about 5% penetration across three products [10] 6. **International Expansion**: AVITA is expanding into Europe, Australia, and Japan, with recent events in Switzerland increasing product visibility [11] 7. **Reimbursement Challenges**: The company faces reimbursement uncertainties, particularly with the execution of Category I CPT codes, which has impacted growth [12][15] 8. **Financial Guidance**: AVITA has provided guidance for 2026, expecting revenue to grow from approximately $72 million in 2025 to between $80 million and $85 million [17][22] 9. **Debt Refinancing**: The company has refinanced its debt with more favorable terms, providing a buffer for cash management and operational focus [17][18] 10. **Clinical Studies**: Ongoing post-market studies for CoHelix and PermeaDerm are expected to yield data that will be shared throughout the year, contributing to clinical credibility [13][14] 11. **Sales Strategy**: The sales team is focused on existing accounts and building relationships with physicians to drive product adoption [20][29] 12. **Cash Management**: AVITA has improved its cash management practices, reducing cash burn and positioning itself for growth without significant additional spending [31][32] Additional Important Content - **Utilization as a KPI**: The company emphasizes tracking utilization rates of its products as a precursor to revenue growth, indicating a focus on operational metrics [33][34] - **Market Sentiment**: There is a strong positive sentiment among physicians regarding the RECELL product, which is seen as a gold standard in burn treatment [19] - **Execution Focus**: The leadership stresses the importance of execution and focus on core business areas to drive growth and operational efficiency [28][29]

Core Insights - AVITA Medical, Inc. announced preliminary financial results for Q4 and fiscal year 2025, along with an outlook for fiscal year 2026, highlighting a shift from stabilization to growth execution [1][2] Financial Performance - Total net revenues for Q4 2025 were approximately $17.6 million, a decrease from $18.4 million in Q4 2024 [6] - Total revenues for the full year 2025 were approximately $71.6 million, an increase of about 11% compared to $64.3 million in 2024, aligning with the company's revised revenue guidance [6] - Full year 2026 revenue is expected to be in the range of approximately $80 to $85 million, representing growth of approximately 12% to 19% compared to 2025 [6] Capital Structure and Financing - The company closed a five-year credit facility with Perceptive Advisors, providing up to $60 million in capital, with an initial funding of $50 million [2][4] - The proceeds from the credit facility will be used to repay outstanding debt and support the growth of the acute wound care portfolio [2][4] - The new credit facility includes trailing twelve-month (TTM) revenue covenants, with an initial TTM revenue covenant set at $68.5 million for Q1 2026 and $73 million for the full year 2026 [3] Clinical and Commercial Developments - The Cohealyx-I study is fully enrolled, and the PermeaDerm-I study has surpassed 75% enrollment as of December 2025, with data expected later in 2026 [6] - The company is positioned to leverage its differentiated position in acute wound care for value creation through commercial execution and clinical advancement [4]

Core Insights - AVITA Medical, Inc. has appointed Joe Woody as a new non-executive Director, while Lou Panaccio has retired after serving as Chairman for over a decade [1][7] Company Leadership Changes - Joe Woody brings over two decades of leadership experience in the medical technology sector, having previously served as CEO of Avanos Medical and President and CEO of Acelity Holdings [2] - Lou Panaccio has been recognized for his significant contributions to the company's commercial and operational strategy during his tenure [2][3] Company Overview - AVITA Medical specializes in therapeutic acute wound care, focusing on innovative solutions that optimize wound healing and accelerate patient recovery [4] - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds, utilizing a patient's own skin to create Spray-On Skin™ Cells [4] - In addition to RECELL, AVITA holds exclusive rights to market and distribute PermeaDerm and Cohealyx, both of which are advanced wound care products [4] International Market Presence - The RECELL System is also approved in international markets for a variety of applications, including thermal burn and trauma wounds, with regulatory clearances in Europe, Australia, and Japan [5]

Core Insights - AVITA Medical, Inc. is a leading company in therapeutic acute wound care, focusing on innovative solutions for wound healing [3][4] - The CEO, Cary Vance, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 [1] - The RECELL System is a key product that utilizes a patient's own skin to create Spray-On Skin™ Cells, enhancing clinical outcomes [3] Company Overview - AVITA Medical specializes in technologies that accelerate patient recovery from wounds [3] - The RECELL System is FDA-approved for treating thermal burn and trauma wounds, and is also recognized in international markets [4] - The company holds exclusive rights to market and distribute PermeaDerm and Cohealyx™, which are additional wound care products [3][4] Presentation Details - A live audio webcast of the upcoming presentation will be available on AVITA Medical's website [2] - A replay of the webcast will be accessible after the event concludes [2]

Summary of AVITA Medical FY Conference Call (December 04, 2025) Company Overview - **Company**: AVITA Medical (NasdaqCM:RCEL) - **Industry**: Therapeutic acute wound care - **Focus**: Acute wounds such as burns, gunshot wounds, and road rashes, aiming to expedite patient recovery and hospital discharge [2][3] Core Products - **RECELL**: First-in-class spray-on skin cell product approved by the FDA in 2019, used in burn centers and trauma centers across the U.S. [4] - **Cohelix**: Collagen-based dermal matrix, bioengineered in partnership with Regenity, which reduces gross margin but increases operating margin [6] - **PermeaDerm**: Biosynthetic dressing that allows visibility of the wound without removal, facilitating air exchange [6] Key Data and Performance Metrics - **RECELL Efficacy**: Patients using RECELL can be discharged 36% faster, with a study of 6,300 burn patients showing a six-day earlier discharge compared to traditional methods [4][17] - **Cost Discipline**: Achieved $10 million in annual cost reductions, maintaining SG&A costs for growth [5] - **Revenue Impact**: Estimated revenue loss of $10-$12 million due to reimbursement issues, with a focus on regaining momentum in 2026 [11][13] Market Potential - **Total Addressable Market (TAM)**: Estimated at $3.5 billion, with AVITA currently capturing about 5% of this market [17] - **Market Share**: Approximately 15%-20% market share in burn centers after five years of presence [17] Financial Performance - **Revenue**: Reported $17 million in revenue, down 13% year-over-year, primarily due to reimbursement challenges [19] - **Gross Margin**: RECELL products maintain a gross margin of 84%, though overall margins may decrease due to the mix of products sold [19][20] - **Cost Management**: Reduced expenses by 24% year-over-year, with a target of $23 million in expenses moving forward [20] Future Outlook - **2026 Guidance**: Anticipated revenue guidance to be provided in early January, with expectations of returning to a growth rate of 29% [20][21] - **International Expansion**: RECELL GO approved in the EU and UK, with pending approval in Australia, utilizing third-party distributors for market entry [15] Additional Insights - **Reimbursement Challenges**: Ongoing issues with CMS and MACs have impacted product usage and demand, but resolution efforts are underway [12][13] - **Patient-Centric Focus**: Emphasis on improving patient outcomes and reducing healthcare costs associated with prolonged hospital stays [16] This summary encapsulates the key points from the AVITA Medical FY Conference Call, highlighting the company's focus on acute wound care, product efficacy, market potential, financial performance, and future outlook.